N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients.
Level 2 - randomized trial
Abstract describes a prospective, randomized, double-masked, placebo-controlled crossover clinical trial alongside in vitro and cohort database data
PubMed 19487926 · doi:10.1097/MJT.0b013e318195e327
What was done
The authors evaluated the antioxidant, reactive oxygen species (ROS) scavenging, and transglycation activities of L-carnosine, N-acetylcarnosine, and second-generation histidyl-hydrazide analogs using in vitro aqueous and liposome lipid membrane models with an iron/ascorbate lipid peroxidation promoter and a glucose-ethylamine Schiff base glycation model. They also evaluated a sustained-release 1% N-acetylcarnosine lubricant eyedrop formula in a prospective, randomized, double-masked, placebo-controlled crossover clinical trial for age-related cataracts, alongside an observational database cohort of over 50,500 patients.
What was found
The abstract provides no numerical data, effect estimates, confidence intervals, or p-values. It qualitatively states that L-carnosine derivatives scavenged ROS and reversed advanced glycation end-product cross-links in vitro, and claims that topical N-acetylcarnosine eyedrops showed significant efficacy, safety, and tolerability for cataracts, glaucoma, macular degeneration, and diabetic retinopathy.
Why it matters
This paper presents the proposed biochemical mechanisms and broad clinical claims for N-acetylcarnosine eyedrops as a non-surgical intervention for age-related cataracts and visual decline.
Limits
The abstract provides no quantitative outcomes, specific sample sizes for the randomized trial arm, follow-up durations, or statistical measures. The reporting is overtly promotional, tied directly to the product developer (Innovative Vision Products, Inc.), and conflates bench model findings, trial claims, and large registry data without reporting transparent results.
Cited by
- supports N-acetylcarnosine eye drops penetrate the eye and act as a decoy to prevent lens glycation in cataracts.